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IMMUNOHISTOCHEMICAL EVALUATION OF P53 EXPRESSION 
IN LUNG CANCER OF PATIENTS WITH PARANEOPLASTIC 
RHEUMATIC SYNDROME
S.A. Lysenko
Pirogov National Medical University, Ministry of Health of Ukraine, Vinnitsa 21018, Ukraine
Aim: To study p53 expression in the tumor tissue of lung cancer (LC) patients with paraneoplastic rheumatic syndrome (PNRS). 
Materials and Methods: There have been used either biopsy or surgically resected tumor samples of 140 LC patients (83 patients 
without PNRS, 57 patients with PNRS). For evaluation of p53 expression in LC samples, immunohistochemical analysis was 
performed. Results: It has been shown that p53 expression in tumor samples from LC patients with PNRS was significantly 
higher compared to that in LC patients without PNRS. It has been shown that p53 expression is more frequently registered in pa-
tients with lung adenocarcinoma with PNRS than in patients with lung adenocarcinoma without this syndrome. Conclusion: The 
presence of PNRS in LC patients with p53 expression is associated with higher aggressiveness of tumor.
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It is well known that oncoproteins can influence 
tumor growth, ability for invasion, metastasis, and 
formation of resistance to anticancer means [1, 2]. 
One of the main oncoproteins is p53 — a protein which 
is a tumor suppressor encoded by TP53 gene in hu-
mans. If a mutation occurs in this gene, the person may 
be more susceptible to the development of cancer [3, 
4]. Oncoprotein p53 regulates the cell cycle and can 
serve as an anti-oncogene which can prevent cancer 
development. Due to this, p53 is sometimes called the 
“Protector of the genome”, “Guardian angel gene” or 
“senior caretaker”, referring to its function to maintain 
stability, preventing genome mutation [5, 6].
Anti-tumor functions of p53 are mediated by: 1) 
inhibition of abnormal cell growth, since it recognizes 
damaged DNA and may induce temporary cessation 
of cell division in the so called control points (check-
point) of the cell cycle [7, 8]; 2) activation of protein 
coding genes, correcting the DNA damage; 3) inhibi-
tion of angiogenesis.
The most universal molecular change in the various 
human neoplasms is the inactivation of the p53 func-
tion. In more than half of all human tumors (50–60% 
of all neoplasms which are over 50 different types) 
the mutation in p53 gene has been detected [9–12]. 
In contrast to other tumor suppressor genes, which are 
characterized by mutations ceasing protein synthesis 
(deletions, formation of stop codons coding frame 
shift, violations in mRNA splicing), the vast majority 
(over 90%) of p53 mutations is a missense mutation 
leading to the replacement of one of the amino acids 
in a protein molecule to another. Another feature of the 
mutations of p53 in tumor cells is that they, in contrast 
to mutations in other tumor suppressor genes, are of-
ten heterozygous, i.e., affect only one of the two alleles 
of the gene. These mutations which lead to dysfunction 
of p53 result in the replication of cells with DNA dam-
age and the accumulation of other oncogenic muta-
tions, contributing further to unregulated cell growth 
and the development of tumor cells [13].
It is known that the majority of patients with lung 
cancer (LC) (more than 50%) showed p53 expression 
[14, 15]. Moreover, LC is associated with paraneoplas-
tic syndrome [16]. In clinical practice, very often this 
syndrome has a rheumatic presentation that has al-
lowed to call it as paraneoplastic rheumatic syndrome 
(PNRS) [17, 18]. Taking into account the relevant 
clinical importance both of p53 expression in tumor 
and PNRS the current study was aimed to evaluate 
the correlation of p53 expression in LC of patients with 
and without PNRS.
MATERIALS AND METHODS
Patients. 140 LC patients were enrolled into the 
study. They were treated at the Vinnitsa Regional Clini-
cal Oncology Center during 2011–2012. The first group 
(control) included 83 LC patients without PNRS, the 
second group (experimental) — 57 LC patients with 
PNRS. The patient age ranged from 40 to 78 years, 
there were 122 (87%) men and 18 (13%) women. The 
author has obtained the consent of Ethical Commit-
tee of Pirogov National Medical University (Vinnitsa, 
Ukraine) to perform this study.
Immunohistochemistry (IHC). Tumor material 
is first treated with 10.0% neutral buffered formalin 
solution, and then embedded in paraffin. Histological 
examination was performed on sections of 4–5 mi-
crons thick and stained with hematoxylin-eosin stain 
(H&E Stain).
Determination of the expression of p53 protein was 
performed on sections where paraffin was removed 
by preliminary unmasking of antigen by citrate buffer 
(pH 6.0) in water for 30 min. Evaluation of the IHC stain-
ing was performed and photographed using a light 
microscope (magnification x100 and x400). As primary 
antibodies, monoclonal antibody (clone DO-7) to the 
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p53 Protein (p53) from “DAKO Cytomation” (Denmark) 
was used. To visualize the products of the reaction, 
EnVision+ system (DAKO) and chromogen DAB+ 
(DAKO) were used.
IHC reaction was evaluated by distinct nuclear 
staining. Then, the number of cells positive for the 
reaction was counted in the area and they were 
in greater quantity. Level of expression of p53 was 
determined by the ratio of colored chromogen DAB+ 
nuclei to unstained nuclei in 10 fields of view and 
expressed in percentage. Thus, we counted the num-
ber of positively stained cells, which came to around 
800–1000 tumor cells. The absence of cells staining 
was assessed as a negative reaction, staining of < 40% 
cells as a weak expression, and > 40% cells as a strong 
expression.
Statistics. Statistical processing of quantitative 
indicators was performed using the parametric criteria 
of Student or Student’s t-test. To test the significance 
of differences of attribute values  in the groups Fish-
er’s exact test was used. Differences were considered 
statistically significant at p < 0.05. Computer software 
“Biostat” was used.
RESULTS
Among all patients, stage I of LC was diagnosed 
in 33 patients (23.6%), II stage — in 47 patients 
(33.6%) and stage III — in 60 patients (42.8%). By his-
tological forms (Table 1) the tumors were classified 
as follows: small cell lung cancer (SCLC, 29 cas-
es — 20.7%)) and non-small cell lung cancer (NSCLC, 
111 cases — 79.3%, which includes adenocarcinoma 
(36 cases — 25.7%) and squamous cell carcinoma 
(75 cases — 53.6%)).
Table 1. Distribution of LC patients by histological forms of cancer
Groups of pa-
tients SCLC Adenocarcinoma
Squamous cell 
carcinoma
LC without PNRS, 
%
19.3 22.9 57.8
LC with PNRS, % 22.8 29.8 47.4
Total, % 20.7 25.7 53.6
In the first group of patients with lung squamous cell 
carcinoma was detected in 57.8% of cases, with adeno-
carcinoma — 22.9% and with SCLC — 19.3% (Table 1). 
It should also be noted that in the second group of pa-
tients, NSCLC were diagnosed in 44 cases (77.2% in re-
lation to all patients with PNRS), and SCLC — in 13 cases 
(22.8%). Among the variations of NSCLC squamous cell 
carcinoma (27 patients, (47.4%) and adenocarcinoma 
(17 patients, 29.8%) were predominant.
It was found that in SCLC samples, p53 expres-
sion (Table 2) was observed more frequently than 
in NSCLC: in 28 (96.6%) of 29 patients. Similarly, 
in NSCLC, p53 expression was observed in tumor 
cells of 80 patients (72.1% of cases in relation to all 
patients with NSCLC).
In general, the expression of p53 protein in tumor 
was observed in 71.1% of patients (59 cases) with 
LC without PNRS and 86.0% of patients (49 cases) 
with PNRS manifestations (Table 2). The difference 
between groups was statistically significant (Fish-
er’s exact test, p < 0.05).
It should also be noted that more than 40% of tumor 
cells were evaluated as p53-positive in patients in both 
groups. In LC patients without PNRS (Fig. 1), the 
number of p53-positive cells was 50.2 ± 6.8%, while 
in LC patients with PNRS manifestations (Fig. 2) the 
average number of p53-positive cells was significantly 
higher, i.e., 72.3 ± 7.5% (Fisher’s exact test, p < 0.05). 
It was observed the link between tumor histology and 
the level of p53 expression in tumor: it was higher 
in squamous cell carcinoma in comparison to SCLC 
in both groups.
Fig. 1. Weak p53 expression in tumor cells (squamous cell LC, 
patient O. without PNRS), × 400
Fig. 2. High p53 expression in tumor cells (squamous cell LC, 
patient I. with PNRS), × 400
As can be seen from Table 2, in patients with SCLC 
without PNRS p53 expression was registered in 93.8% 
cases (15 out of 16), while in patients with PNRS (Fig. 3) 
it was 100%. At the same time the difference between 
the groups was not statistically significant (p > 0.1).
In all NSCLC patients without PNRS (44 patients, 
53.0% among all patients in the first group) p53 ex-
pression was observed in 11 adenocarcinoma (13.3%) 
and 33 squamous cell carcinoma (39.8%) cases. 
Among NSCLC patients with PNRS the expression 
of p53 in tumor was observed in 36 patients (63.2% 
of all cases in the second group): 15 adenocarcinoma 
(26.3%) and 21 squamous cell carcinoma (36.8%). 
It should also be noted that p53 expression in NSCLC 
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was most often associated with adenocarcinoma, and 
more precisely in the presence of PNRS (Fig. 4, 5). 
Fig. 3. High p53 expression in tumor cells (SCLC, patient N. 
with PNRS), ×400
Fig. 4. p53 expression in tumor cells (lung adenocarcinoma, 
patient L. without PNRS), × 400
Fig. 5. p53 expression in tumor cells (lung adenocarcinoma, 
patient K. with PNRS), × 400
It was determined that the number of patients 
with adenocarcinoma and PNRS (15 cases) and p53-
positive tumor in relation to all cases of adenocarci-
noma in the second group (17 cases) was 88.2%, that 
is higher than the number of p53-positive adenocarci-
noma (57.9%, 11 cases out of 19) in patients without 
PNRS (Fisher’s exact test, p < 0.05) (Table 2).
In the cases of squamous cell carcinoma, the diffe-
rence between p53 expression in tumor samples from 
the first and the second groups (p > 0.1) was statisti-
cally insignificant (Table 2). Moreover, the p53 expres-
sion in squamous cell carcinoma of patients without 
PNRS was observed in 68.8% of cases (33 of 48), 
while in patients with the similar histological type 
with manifestations of PNRS was observed in 77.8% 
of cases (21 of 27).
Table 2. р53-positive cells in LC
Histological 
form
p53-positive cells in LC
Patients without PNRS Patients with PNRS
Number 
of patients
Number 
of posi tive 
samples, %
Number 
of patients
Number of pos-
itive samples, 
%
SCLC 15 93.8 13 100
Adenocarcinoma 11 57.9 15 88.2
Squamous 33 68.8 21 77.8
Total 59 71.1 49 86.0
DISCUSSION
Analyzing literature on this subject, it should 
be noted that other researchers did not study the 
p53 expression in LC patients with manifestations 
of PNRS. The general study of the expression of the 
p53 in LC and its relation to the degree of malignancy, 
the distribution process, prognosis and survival of pa-
tients was found [19, 20]. Some studies in recent years 
indicate that the expression of p53 in tumor is found 
in 45–80% of patients with LC [14]. In SCLC a high 
amount of p53-positive cells (70% of patients or more) 
was found when compared to NSCLC (45–65% of pa-
tients) [21, 22]. Also the correlation between high le-
vels of p53-positive cells in tumor and the distribution 
of tumor process was noted (patients with metastases 
to regional lymph nodes) for both histological forms 
of LC (NSCLC and SCLC) [14, 23, 24]. There is also 
evidence of mutual positive correlation of p53 expres-
sion with expression of proliferation marker Ki-67 [14, 
20]. It was demonstrated that p53 expression is the 
prognostic factor in LC, in particular its high expres-
sion was detected in patients with a poor outcomes 
(metastasis, tumor recurrence and death) [25]. Also, 
a high level of p53-positive cells in tumor demonstrates 
the negative impact on the survival of patients with LC, 
especially radically operated patients with stage III 
of NSCLC [23–26]. Among such patients, the number 
of p53-positive cells in tumor greater than 10% is also 
one of the 6 most important factors for prognosis 
as well as choice of treatment [15].
Our studies confirm that the expression 
of p53 in LC depends on the histological structure 
of the tumor, as well as on the clinical characteristics 
of the patient, in particular the presence of PNRS. Thus, 
in the group of LC patients with PNRS significantly 
higher level of p53-positive tumor cells in comparison 
to those in LC patients without PNRS has been shown 
that may indicate more aggressive tumor.
Similarly, in LC patients with PNRS a significantly 
higher number of p53-positive tumor cells were 
found in comparison with those in patients without 
PNRS. This fact indicates a higher malignant and 
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aggressive nature of tumors in LC patients with 
PNRS. This suggestion may be supported by the fact 
that high p53 expression is a negative prognostic factor 
for LC patients [14, 15, 20–22].
We observed that the frequency of high p53 expres-
sion in lung adenocarcinoma was higher in patients 
with PNRS than in patients with lung adenocarci-
noma without PNRS. It should also be noted that the 
identification of PNRS among patients with LC leads 
to a more complete assessment of the prognosis, the 
degree of malignancy and helps to further improve the 
treatment of patients.
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